These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21224321)

  • 1. Orphan drugs. EU regulations.
    Mariz S; Llinares J; Westermark K
    BMJ; 2011 Jan; 342():d136. PubMed ID: 21224321
    [No Abstract]   [Full Text] [Related]  

  • 2. The problem of orphan drugs.
    Ferner RE; Hughes DA
    BMJ; 2010 Nov; 341():c6456. PubMed ID: 21081597
    [No Abstract]   [Full Text] [Related]  

  • 3. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding orphan drug regulations: an EU and U.S. comparative analysis.
    Grienenberger A
    J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Orphan drugs in France (2001-2005): access to information and characteristics].
    Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
    Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing rarity in the context of orphan medicinal product designation in the European Union.
    Tsigkos S; Hofer MP; Sheean ME; Mariz S; Larsson K; Naumann-Winter F; Fregonese L; Sepodes B
    Drug Discov Today; 2018 Mar; 23(3):681-686. PubMed ID: 28647377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EU adopts legislation to promote drug development for rare diseases.
    Whyte B
    Bull World Health Organ; 2000; 78(5):711. PubMed ID: 10859868
    [No Abstract]   [Full Text] [Related]  

  • 13. Promoting the development of drugs against rare diseases: what more should be done?
    Westermark K; Llinares J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
    [No Abstract]   [Full Text] [Related]  

  • 14. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

  • 15. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating and improving orphan drug regulations in Europe: a Delphi policy study.
    Picavet E; Cassiman D; Simoens S
    Health Policy; 2012 Nov; 108(1):1-9. PubMed ID: 22989856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 18. [Orphan drugs].
    Kolár J; Chalabala M; Srámková H
    Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.